Fresh off grossing $103.5 million in an overstuffed IPO, Cambridge, MA’s Sage Therapeutics has secured the promise of a speedy FDA review for its top prospect, a treatment for a rare seizure disorder.

…read more

Source: Sage takes to the FDA fast track with its lead rare disease drug


0 No comments